Drug intelligence / Profile preview

disulfiram + efavirenz

Development stage
Phase 1
Lead developer
Bristol Myers Squibb
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination of two small molecule drugs: **disulfiram**, an aldehyde dehydrogenase inhibitor used as a deterrent in the treatment of alcohol dependence, and **efavirenz**, a non-nucleoside reverse transcriptase inhibitor used as part of antiretroviral therapy for HIV infection. Disulfiram works by irreversibly inhibiting aldehyde dehydrogenase, leading to accumulation of acetaldehyde when alcohol is consumed, causing unpleasant effects that discourage drinking[1][3]. Efavirenz inhibits HIV reverse transcriptase by binding to an allosteric site on the enzyme, preventing viral replication[2]. When co-administered, efavirenz can increase the inhibitory effect of disulfiram on aldehyde dehydrogenase due to induction of CYP3A4-mediated metabolism that increases levels of the active metabolite responsible for ALDH inhibition[1][4]. This combination may be considered in patients with co-occurring HIV infection and alcohol use disorder.

Brand names
Stocrin
Other names
tetraethylthiuram disulfideNNRTI
02

Targets

ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on disulfiram + efavirenz.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on disulfiram + efavirenz.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call